About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. For more information, please visit www.hyperiontx.comForward-Looking Statements: This press release includes forward-looking statements reflecting management's current beliefs and expectations about future events; these forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectations regarding the timing and effectiveness of any commercial launch of RAVICTI, the timing of availability of RAVICTI to physicians and patients, our plans with respect to distribution of RAVICTI with specialty pharmacies, the launch of a dedicated call center and our plans with respect to the development of RAVICTI to treat HE. Forward-looking statements in this release involve substantial risks and uncertainties that could cause future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to: the success and timing of commercialization and distribution efforts; the fact that the patient population suffering from UCD is small and has not been established with precision; uncertain ability to hire and retain qualified personnel to assist with those commercialization and distribution efforts; risks associated with our ability to obtain adequate commercial and clinical supplies of RAVICTI; uncertainties associated with physician acceptance of RAVICTI, patient and physician response to pricing of the drug and government or insurance reimbursement of the drug; and the uncertain ability to raise sufficient capital to complete the development and commercialization of RAVICTI in HE. Hyperion undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see for example Hyperion's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on February 1, 2013 as well as Hyperion's Quarterly Report on Form 10-Q filed on November 7, 2012.
CONTACT: Myesha Edwards, Investor Relations (650) 745-7829 firstname.lastname@example.org Kristie Kuhl, Media Relations (203) 556-7417 email@example.com